Thyrocare

Tests you can trust

Name : xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Date : xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Test Asked : Roma (Risk Of Ovarian Malignancy)

Report Status:



9 out of 10 Doctors trust that Thyrocare **reports are accurate & reliable***

98% Reports released within **06 Hours** of sample reaching the lab+

Samples Processed in **NABL Accredited** Labs#

700+ Tests & Profiles

Temperature-Controlled Sample Logistics

Unique Barcode Tracking & Reports with QR Code Verification

Fully Automated Machines Inspected Daily

Abnormal Values Re-Checked Twice

Reports Verified By Expert MD Pathologists Stationed at Every Lab

Accredited by

NABL From 2005#

ISO 9001: 2015 - From 2015

CAP From 2007

Dummy Report

PROCESSED AT :

Thyrocare
Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 98706 66333 wellness@thyrocare.com

*9 out of 10 Doctors Trust that Thyrocare Reports are **Accurate & Reliable***

NAME : XXXXXXXXXXXXXXXX
REF. BY : XXXXXXXXXXXXXXXX
TEST ASKED : ROMA (RISK OF OVARIAN MALIGNANCY)

HOME COLLECTION :
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PATIENTID :

TEST NAME	TECHNOLOGY	VALUE	UNITS
HUMAN EPIDIDYMIS PROTEIN 4	C.M.I.A	28.3	pmol/L

Bio. Ref. Interval. :-

Females :
Pre Menopausal : <=70 pmol/L
Post Menopausal : <=140 pmol/L

Interpretation:-
The level of HE4 cannot be used as an absolute evidence for presence or absence of malignant disease and HE4 assay should not be used as a cancer screening test.
The results obtained should be interpreted in conjunction with other methods in accordance with standard clinical management guidelines. If HE4 results are inconsistent with clinical evidence, additional testing is recommended.
Patients with confirmed ovarian cancer may have HE4 values similar to normal healthy women. The use of this assay is not recommended in monitoring patients with known mucinous or germ cell tumors (as these rarely produce HE4) . Elevated levels of HE4 antigen may be seen in patients with non malignant disease.
Specimens containing HAMA (Human anti mouse antibodies), heterophile antibodies etc may give anomalous values . The values may show variation if different methodologies, technologies, reagent brand, calibrators used and also variation seen due to various pathological and physiological factors

Reference - Abbott HE4 Reagent Kit insert

Please correlate with clinical conditions.
Method:- FULLY AUTOMATED CHEMI LUMINESCENT MICROPARTICLE IMMUNOASSAY

Dummy Report

Sample Collected on (SCT) : Sample collection time
Sample Received on (SRT) : Sample receiving time at Lab
Report Released on (RRT) : Report release time
Sample Type : SERUM
Labcode :
Barcode :

Doctor 1 Sign Doctor 2 Sign

PROCESSED AT :

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Thyrocare
Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 98706 66333 wellness@thyrocare.com

9 out of 10 Doctors Trust that Thyrocare Reports are Accurate & Reliable

NAME : XXXXXXXXXXXXXXXX
REF. BY : XXXXXXXXXXXXXXXX
TEST ASKED : ROMA (RISK OF OVARIAN MALIGNANCY)

HOME COLLECTION :
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PATIENTID :

TEST NAME	TECHNOLOGY	VALUE	UNITS
CA125	C.M.I.A	4.2	U/mL

Bio. Ref. Interval. :-

Less than 35 U/mL

Clinical Significance:

CA125 is used in monitoring response to therapy for patients with epithelial ovarian cancer. CA125 is also detects or monitors whether there is a recurrence of cancer or malignancy after surgical removal of tumor or radiation therapy or chemotherapy (antineoplastic drugs). The test is used for follow up in High-Risk cases, where family history of Ovarian Cancer is noted. CA125 may normally be increased in early pregnancy and during menstruation. It can also be increased in diseases such as Pelvic Inflammatory Disease or Endometriosis and sometimes in Hepatitis and Cirrhosis of the Liver.

Kit validation Reference :
Bast RC Jr., Feeney M, Lazarus H, et al. Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma. J Clin Invest 1981;68:1331-7.

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED CHEMI LUMINESCENT MICROPARTICLE IMMUNOASSAY

Dummy Report

Sample Collected on (SCT) : Sample collection time
Sample Received on (SRT) : Sample receiving time at Lab
Report Released on (RRT) : Report release time
Sample Type : SERUM
Labcode :
Barcode :

Doctor 1 Sign Doctor 2 Sign

PROCESSED AT :

Thyrocare
Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703 98706 66333 wellness@thyrocare.com

*9 out of 10 Doctors Trust that Thyrocare Reports are **Accurate & Reliable***

NAME : XXXXXXXXXXXXXXXX

REF. BY : XXXXXXXXXXXXXXXX

TEST ASKED : ROMA (RISK OF OVARIAN MALIGNANCY)

PATIENTID :

HOME COLLECTION :
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
ROMA - PREMENOPAUSAL	CALCULATED	1.88	%

Bio. Ref. Interval. :
Pre menopausal : >=7.4 % High Risk
< 7.4 % Low Risk

Method : DERIVED FROM HE4 AND CA125 VALUES

ROMA - POSTMENOPAUSAL	CALCULATED	2.76	%

Bio. Ref. Interval. :
Post menopausal : >=25.3 % High Risk
< 25.3 % Low Risk

Method : DERIVED FROM HE4 AND CA125 VALUES

Please correlate with clinical conditions.

Clinical significance :
ROMA (Risk of Malignancy Algorithm) is intended as an aid in assessing whether a premenopausal or postmenopausal woman who presenting with an ovarian adnexal mass is at high or low likelihood of having malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18; ovarian adnexal mass present for which surgery is planned, and who has not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. ROMA is not intended as a screening or stand-alone or tumor-monitoring assay. Tumor monitoring usingHE4and/or CA125 should be ordered separately.

FDA has approved ROMA for distinguishing malignant from benign pelvic masses recently in 2011

References :

1. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28. Published online 2019 Mar 27. doi: 10.1186/s13048-019-0503-7
2. Diagnostic Value of Risk of Malignancy Algorithm (ROMA) in adnexal masses. Obstet Gynaecol India. 2020 Jun; 70(3):214-219. Published online 2019 Dec 23. doi: 10.1007/s13224-019-01295-3

~~ End of report ~~

Dummy Report

Sample Collected on (SCT) : Sample collection time

Sample Received on (SRT) : Sample receiving time at Lab

Report Released on (RRT) : Report release time

Sample Type : SERUM

Labcode :

Barcode :

Doctor 1 Sign Doctor 2 Sign

CUSTOMER DETAILS

As declared in our data base

Name: xxxxx **Age:** xxxxx **Sex:** xxxxx

Barcodes/Sample_Type	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Labcode	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Ref By	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Sample_Type/Tests	:	SERUM:ROMA (RISK OF OVARIAN MALIGNANCY)
Sample Collected At	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Sample Collected on (SCT)	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Report Released on (RRT)	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Amount Collected	:	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Dummy Report

CONDITIONS OF REPORTING


- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report.
- Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc
- For clinical support please contact @8450950852,8450950853,8450950854 between 10:00 to 18:00

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- **Name** - The name is as declared by the client and recored by the personnel who collected the specimen.
- **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- **Reference Range** - Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints or feedback, write to us at **info@thyrocare.com** or call us on **022-3090 0000 / 61 30 00**
- SMS:<Labcode No.>to **9666333**





*+T&C Apply, # Upto 95% Samples in NABL Accredited Labs, * As per a survey on doctors' perception of laboratory diagnostics (IJARIIT,2023)*